RT Journal Article
SR Electronic
T1 Echocardiography-Based Deep Learning Model to Differentiate Constrictive Pericarditis and Restrictive Cardiomyopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.29.22282900
DO 10.1101/2022.11.29.22282900
A1 Chao, Chieh-Ju
A1 Jeong, Jiwoong
A1 Arsanjani, Reza
A1 Kim, Kihong
A1 Ayoub, Chadi
A1 Grogan, Martha
A1 Kane, Garvan
A1 Banerjee, Imon
A1 Oh, Jae K
YR 2022
UL http://medrxiv.org/content/early/2022/11/29/2022.11.29.22282900.abstract
AB Background Constrictive pericarditis (CP) is an uncommon but reversible cause of diastolic heart failure if appropriately identified and treated. Although echocardiography can detect CP based on characteristic cardiac motion and Doppler findings, its diagnosis remains a challenge for clinicians. Artificial intelligence (AI) may enhance identification of CP. We proposed a deep learning approach based on transthoracic echocardiography (TTE) to differentiate CP from restrictive cardiomyopathy (RCM).Methods Patients with a confirmed diagnosis of CP and cardiac amyloidosis (CA, as the representative disease of RCM) at Mayo Clinic Rochester from 1/2003-12/2021 were identified to extract baseline demographics and the apical 4 chamber (A4C) view from TTE studies. The cases were split into a 60:20:20 ratio for training, validation, and held-out test sets of the ResNet50 deep learning model. The model performance (differentiating CP and CA) was evaluated in the test set with the area under the curve (AUC). GradCAM was used for model interpretation.Results A total of 381 patients were identified, including 184 (48.3%) CP, and 197 (51.7%) CA cases. The mean age was 68.7±11.4, and 72.8% were male. ResNet50 had a performance with an AUC to differentiate the 2-class classification task (CP vs. CA, AUC 0.97). The GradCAM heatmap showed activation around the ventricular septal area.Conclusion With a standard A4C view, our AI model provides a platform for the early and accurate detection of CP, allowing for improved workflow efficiency and prompt referral for more advanced evaluation and intervention of CP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mayo Clinic IRB; protocol#19-009303I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript A4Capical 4 chamber viewAIArtificial IntelligenceAUCarea under the curveCAcardiac amyloidosisCPconstrictive pericarditisRCMrestrictive cardiomyopathyTTEtransthoracic echocardiography